Influential predictors of azithromycin pharmacokinetics: a systematic review of population pharmacokinetics
- PMID: 40372973
- PMCID: PMC12082735
- DOI: 10.1080/07853890.2025.2496792
Influential predictors of azithromycin pharmacokinetics: a systematic review of population pharmacokinetics
Abstract
Introduction: Azithromycin exhibits significant pharmacokinetic variability. Thus, dosage optimization is crucial for optimal therapeutic outcomes. This systematic review aims to analyze the population pharmacokinetics (PopPK) of azithromycin and identify key covariates influencing its pharmacokinetics.
Methods: A systematic search was conducted in PubMed, Scopus, and ScienceDirect databases. Azithromycin PopPK studies conducted using a nonlinear mixed-effects approach in humans were included. Studies published in non-English or non-Thai languages were excluded. Moreover, studies with insufficient information, review articles, or registered protocols were also excluded. The reporting quality of the included studies was assessed using adapted guidelines from a previously published framework. Data on study designs, population characteristics, pharmacokinetic parameters, and influential predictors were summarized. Forest plots were used to determine the influence of covariates on azithromycin pharmacokinetics.
Results: Fifteen studies were included. The volume of distribution (Vd) and the clearance in preterm newborns were approximately 68%-94% and 87%-100% lower than those of adults and children. Pregnant women had approximately 85% higher Vd. Patients with alanine aminotransferase >40 U/L had about 24% lower clearance. Azithromycin clearance slightly decreased with advancing age. There is limited data on the relationship between azithromycin exposure and safety outcomes. Finally, most models were not externally evaluated.
Conclusions: Significant predictors for azithromycin pharmacokinetics were identified in this review. However, the limited external validation of most models restricts their clinical utility. Further research is necessary to confirm the models' external validity.
Prospero registration: CRD42024609484.
Keywords: Azithromycin; Monte Carlo simulations; individualized dose; nonlinear mixed effect model; population pharmacokinetics.
Conflict of interest statement
No potential conflict of interest was reported by the authors.
Figures
Similar articles
-
Pharmacokinetics, microbial response, and pulmonary outcomes of multidose intravenous azithromycin in preterm infants at risk for Ureaplasma respiratory colonization.Antimicrob Agents Chemother. 2015 Jan;59(1):570-8. doi: 10.1128/AAC.03951-14. Epub 2014 Nov 10. Antimicrob Agents Chemother. 2015. PMID: 25385115 Free PMC article. Clinical Trial.
-
Population Pharmacokinetic Modeling of Azithromycin Eyedrops in Tears Following Single-Dose Topical Administration in Healthy Volunteers.Eur J Drug Metab Pharmacokinet. 2019 Jun;44(3):371-378. doi: 10.1007/s13318-018-0522-6. Eur J Drug Metab Pharmacokinet. 2019. PMID: 30357610 Clinical Trial.
-
Population Pharmacokinetics and Individualized Medication of Azithromycin for Injection in Children Under 6 Years Old.J Pharm Sci. 2024 May;113(5):1351-1358. doi: 10.1016/j.xphs.2024.01.012. Epub 2024 Jan 20. J Pharm Sci. 2024. PMID: 38253224
-
A Review of Vancomycin, Gentamicin, and Amikacin Population Pharmacokinetic Models in Neonates and Infants.Clin Pharmacokinet. 2025 Jan;64(1):1-25. doi: 10.1007/s40262-024-01459-z. Epub 2025 Jan 16. Clin Pharmacokinet. 2025. PMID: 39821208 Free PMC article. Review.
-
Intravenous azithromycin.Ann Pharmacother. 1999 Feb;33(2):218-28. doi: 10.1345/aph.18046. Ann Pharmacother. 1999. PMID: 10084418 Review.
References
-
- Krudsood S, Silachamroon U, Wilairatana P, et al. . A randomized clinical trial of combinations of artesunate and azithromycin for treatment of uncomplicated Plasmodium falciparum malaria in Thailand. Southeast Asian J Trop Med Public Health. 2000;31(4):801–807. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical